Publicaciones en colaboración con investigadores/as de Johns Hopkins University School of Medicine (46)

2024

  1. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

    Journal of Hepatology

  2. Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities

    Journal for immunotherapy of cancer, Vol. 12, Núm. 5

2022

  1. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  2. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

    Journal of Translational Medicine, Vol. 20, Núm. 1

  3. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

    Advanced Science, Vol. 9, Núm. 26

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Integrated Multiomics Reveals Glucose Use Reprogramming and Identifies a Novel Hexokinase in Alcoholic Hepatitis

    Gastroenterology, Vol. 160, Núm. 5, pp. 1725-1740.e2

  5. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  6. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2020

  1. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis

    The Lancet Haematology, Vol. 7, Núm. 10, pp. e746-e755

  2. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 8, pp. 1940-1951

2019

  1. Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival

    BMC Cancer, Vol. 19, Núm. 1

  2. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis

    Translational Oncology, Vol. 12, Núm. 1, pp. 1-7

  3. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Heterogeneity within the PF-EPN-B ependymoma subgroup

    Acta Neuropathologica, Vol. 136, Núm. 2, pp. 227-237

  2. OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Annals of Oncology, Vol. 29, Núm. 2, pp. 431-438

  3. OV21/PETROC: A randomized gynecologic cancer intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Obstetrical and Gynecological Survey

2017

  1. Technical aspects of transcarotid artery revascularization using the ENROUTE transcarotid neuroprotection and stent system

    Journal of Vascular Surgery, Vol. 65, Núm. 3, pp. 916-920